Abstracts Archive - Page 1954 of 2425 - ACR Meeting Abstracts

Abstract Number: 1480 • 2014 ACR/ARHP Annual Meeting
Dose Selection of GLPG0634, a Selective JAK1 Inhibitor, for Rheumatoid Arthritis Phase 2B Studies: PK/PD and Exposure-DAS28 Modeling Approach
Florence Namour¹, Chantal Tasset², Béatrice Vayssièrre³, Gerben van 't Klooster⁴, Paul Diderichsen⁵ and Eugène Cox⁶, ¹102 Avenue Gaston Roussel, Galapagos SASU, Romainville, France, ²Generaal de Wittelaan L11 A3, Galapagos NV, Mechelen, Belgium, ³Galapagos SASU, Romainville, France, ⁴Galapagos NV, Mechelen, Belgium, ⁵Quantitative Solution, Breda, Netherlands, ⁶Quantitative Solutions, Breda, Netherlands
Background/Purpose: GLPG0634 is an orally-available, selective Janus kinase 1 (JAK1) inhibitor. Selective inhibition of JAK1 may combine favorable safety and clinical efficacy profiles with rapid…
Abstract Number: 1479 • 2014 ACR/ARHP Annual Meeting
Impact of Clinical Remission on Physical Function in Patients with Rheumatoid Arthritis Treated with ALX-0061: Post-Hoc Analysis of Phase I/II Data
Katrien Van Beneden¹, Katrien Verschueren¹, Wouter Willems¹, Heidi Wouters¹, Joke D'Artois¹, Katelijne De Swert¹, Steven De Bruyn¹ and Gerhard Arold², ¹Clinical Development, Ablynx nv, Zwijnaarde, Belgium, ²Medical Affairs, PRA International GmbH, Berlin, Germany
Background/Purpose: ALX-0061 is a monovalent IL-6R targeting Nanobody, inhibiting signaling via soluble and membrane IL-6R. The safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of ALX-0061 was…
Abstract Number: 1478 • 2014 ACR/ARHP Annual Meeting
Pharmacokinetics, Bioavailability and Safety of a Modified-Release Once-Daily Formulation of Tofacitinib in Healthy Volunteers
M. Lamba¹, R. Wang¹, T. Fletcher², C. Alvey¹, A. Hazra¹, J. Kushner¹, J. Larmann¹ and T. Stock², ¹Pfizer Inc, Groton, CT, ²Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). The efficacy and safety of an immediate-release (IR) formulation…
Abstract Number: 1477 • 2014 ACR/ARHP Annual Meeting
Overweight and Obesity Are Associated with Reduced Risk of Rheumatoid Arthritis in Men, but Not in Women
Carl Turesson¹, Ulf Bergström², Mitra Pikwer^2,3, Jan-Åke Nilsson² and Lennart Jacobsson^2,4, ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Rheumatology Unit, Mälar Hospital, Eskilstuna, Sweden, ⁴Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden
Background/Purpose There are diverging results on the relation between body mass index (BMI) and risk of rheumatoid arthritis (RA). Several studies have reported different patterns…
Abstract Number: 1476 • 2014 ACR/ARHP Annual Meeting
A Dose Response Relationship Between Shared Epitope and ACPA Level: But Not All SE Alleles Are Created Equal
Jeremy Sokolove¹, Lauren J. Lahey¹, Catriona Wagner², Irene Smolik³, David B. Robinson⁴, Elizabeth D. Ferucci⁵, Marianna Newkirk⁶, Marvin Fritzler⁷, William H. Robinson⁸ and Hani El-Gabalawy⁹, ¹VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ²VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, ³Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ⁴Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, ⁵Division of Community Health Services, Alaska Native Tribal Health Consortium, Anchorage, AK, ⁶McGill University, Montreal, QC, Canada, ⁷Medicine, University of Calgary, Calgary, AB, Canada, ⁸VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁹University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Indigenous North American populations have high prevalence of seropositive RA. The Cree/Ojibway population in Central Canada and the Alaska Native population have a high prevalence…
Abstract Number: 1475 • 2014 ACR/ARHP Annual Meeting
Porphyromonas Gingivalis and Bone Turnover Biomarkers in Rheumatoid Arthritis
Manpreet Sethi¹, Anand Dusad¹, Harlan Sayles², Geoffrey Thiele³, Jeffrey Payne⁴, Michael J. Duryee⁵, Bart Hamilton⁶ and Ted R. Mikuls⁷, ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³Int Med/Sec of Rheum/Immun, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁴College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, ⁵Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶University of Nebraska Medical Centre and Omaha VA Medical Center, Omaha, NE, ⁷Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Periodontitis (PD) associated with P. gingivalis has been implicated as a risk factor for rheumatoid arthritis (RA). We have previously demonstrated that RA patients…
Abstract Number: 1474 • 2014 ACR/ARHP Annual Meeting
Anti-Peptidyl Arginine Deiminase 4 Antibodies in African-Americans with Rheumatoid Arthritis and Radiographic Scores
Iris Navarro-Millan¹, Andrew Westfall², Erika Darrah^3,4, Antony Rosen⁵, Ted R. Mikuls⁶, Richard Reynolds², Maria I. Danila⁷, Jeffrey R. Curtis² and S. Louis Bridges Jr.^2,8, ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Rheumatology, The Johns Hopkins University, Baltimore, MD, ⁴5200 Eastern Ave MFL Bldg Cntr, The Johns Hopkins University, Division of Rheumatology, Baltimore, MD, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁷Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The presence of serum autoantibodies to peptidyl arginine deiminase 4 (PAD4) have been associated with erosive rheumatoid arthritis (RA) in populations that were composed…
Abstract Number: 1473 • 2014 ACR/ARHP Annual Meeting
Manocept-Cy3 Localizes CD206 + Macrophages in Synovial Tissue and Fluid from Rheumatoid Arthritis Patients Differentially Compared to Controls
Nicholas A. Young¹, Larry Schlesinger², Thomas J. Rosol³, Fred Cope⁴ and Wael N. Jarjour⁵, ¹Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ²Center for Microbial Interface Biology, Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH, ³The Ohio State University College of Veterinary Medicine, Columbus, OH, ⁴Navidea Biopharmaceuticals, Dublin, OH, ⁵Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: Early identification of rheumatoid arthritis (RA) would allow aggressive treatment with disease modifying rheumatic drugs and provide a system to monitor patient responses. Therefore,…
Abstract Number: 1452 • 2014 ACR/ARHP Annual Meeting
Timing of Decisions to Adjust Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy for Rheumatoid Arthritis (RA) Patients with Active Disease in a Usual Practice Setting
Yomei Shaw¹, Chung-Chou H. Chang², Marc C. Levesque³, Julie M. Donohue⁴, Kaleb Michaud^5,6 and Mark S. Roberts¹, ¹Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ²Department of Medicine, University of Pittsburgh Department of Medicine, Pittsburgh, PA, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA, ⁴Health Policy & Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ⁵National Data Bank for Rheumatic Diseases, Wichita, KS, ⁶Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Current guidelines recommend that rheumatoid arthritis (RA) patients with poor response to their current regimen of disease modifying anti-rheumatic drugs (DMARDs) have therapy adjusted…
Abstract Number: 1453 • 2014 ACR/ARHP Annual Meeting
Gastrointestinal Risk Factors and Treatment Patterns of Rheumatoid Arthritis Versus Osteoarthritis Patients in Korea
Eun Young Lee¹, Sang Heon Lee², Hyo-Jin Kim³ and Korea RA/OA OR Group, ¹Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ²Dept of Internal Medicine, Konkuk University Hospital, Seoul, South Korea, ³Pfizer Tower, 1-11, Hoehyun-Dong 3-Ga, Jung-Gu, Seoul, South Korea
Background/Purpose Little is known about local data of the gastrointestinal risk faocts (GI) and treatment pattenrs in rheumatoid arthritis (RA) and osteoarthritis (OA) patients. This study aimed to investigate and compare…
Abstract Number: 1451 • 2014 ACR/ARHP Annual Meeting
Use of Analgesics in Patients with Knee and/or Hip Osteoarthritis: Results from the Amsterdam Osteoarthritis Cohort
Joyce van Tunen¹, Marike van der Leeden^1,2, Martin van der Esch¹, Leo D. Roorda¹, Willem F. Lems^3,4 and Joost Dekker⁵, ¹Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ²Rehabilitation Medicine/EMGO, VU University Medical Center, Amsterdam, Netherlands, ³Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁴Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose Use of analgesics is recommended by international guidelines to reduce pain complaints related to knee and/or hip osteoarthritis. Underuse of analgesics might be substantial…
Abstract Number: 1450 • 2014 ACR/ARHP Annual Meeting
Spironolactone As a Novel DMARD in Rheumatoid Arthritis
Inderjeet Verma¹, Pawan Krishan² and Ashit Syngle³, ¹Deptt. of Pharmaceutical Sciences & Drug Resaerch, Punjabi University Patiala, India, Chandigarh, India, ²Deptt. of Pharmaceutical Sciences & Drug Research, Punjabi University Patiala, India, Patiala, India, ³Cardio Rheuma, Healing Touch City Clinic, Fortis Multispeciality Hospital, Chandigarh, India
Background/Purpose: Synthetic disease-modifying antirheumatic drugs (DMARDs) though effective have limitations often requiring use of expensive parenteral biologic DMARDs in Rheumatoid Arthritis (RA). Hence there is…
Abstract Number: 1448 • 2014 ACR/ARHP Annual Meeting
A Questionnaire Assessment of Knowledge about Methotrexate of Patients with Rheumatoid Arthritis
Françoise Fayet¹, Carine Savel¹, Malory Rodere², Bruno Pereira³, Dihya Abdi¹, Marion Couderc Sr.⁴, Sylvain Mathieu⁵, Anne Tournadre⁶, Sandrine Malochet-Guinamand⁶, Martin Soubrier⁷ and Jean Jacques Dubost⁸, ¹Rheumatology, CHU Gabriel-Montpied, Clermont-ferrand, France, ²Rheumatology, CHU Gabriel-Montpied, Clermont-Ferrand, France, ³Clinical research department, Clermont-Ferrand, France, ⁴Chu G.Montpied, Clermont Ferrand, France, ⁵Hopital Gabriel Montpied, Clermont Ferrand, France, ⁶Rheumatology CHU Gabriel Montpied, Clermont-Ferrand, France, ⁷COMEDRA trial group, Paris, France, ⁸Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France
Background/Purpose Methotrexate is the reference treatment for rheumatoid arthritis (RA). It has potentially serious side effects which can be prevented by an improvement in patient’s…
Abstract Number: 1447 • 2014 ACR/ARHP Annual Meeting
Implementing American College of Rheumatology (ACR) Quality Indicators for Rheumatoid Arthritis (RA) in the United Arab Emirates (UAE)
Hannah Beermann, Joyce Daoud and Humeira Badsha, Dr. Humeira Badsha Medical Centre, Dubai, United Arab Emirates
Background/Purpose Prior to the establishment of RA standards set by the ACR, a widespread discrepancy was formed between practices, which were treating patients with RA…
Abstract Number: 1446 • 2014 ACR/ARHP Annual Meeting
Utility of Ultrasound in the Nuffield Orthopaedic Centre Emergency Rheumatology Clinic: Survey of Clinical Effectiveness
Kuljeet Bhamra¹, Catherine Swales¹, Matthew Seymour¹, Catherine McClinton¹ and Peter C. Taylor², ¹Nuffield Department of orthopaedics,rheumatology and musculosketal sciences, University of Oxford, Oxford, United Kingdom, ²NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom
Background/Purpose The aim of the survey was to evaluate the impact of clinic-based musculoskeletal ultrasonography (MSUS) on diagnosis and management of cases seen in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].